MBX Biosciences Enters Material Definitive Agreement
Ticker: MBX · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1776111
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
MBX Bio just signed a big deal, filing shows material agreement on 9/24.
AI Summary
MBX Biosciences, Inc. entered into a Material Definitive Agreement on September 24, 2025. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and headquartered in Carmel, Indiana.
Why It Matters
This filing indicates a significant new contract or partnership for MBX Biosciences, which could impact its future revenue and operations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-42272 — Commission File Number (Identifies the company's SEC filing history.)
- 84-1882872 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- MBX Biosciences, Inc. (company) — Registrant
- September 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Carmel, Indiana (location) — Principal Executive Offices
- (317) 659-0200 (phone_number) — Registrant's Telephone Number
FAQ
What type of Material Definitive Agreement did MBX Biosciences, Inc. enter into?
The filing states that MBX Biosciences, Inc. entered into a Material Definitive Agreement on September 24, 2025, but the specific details of the agreement are not provided in this section of the 8-K.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 24, 2025.
Where is MBX Biosciences, Inc. headquartered?
MBX Biosciences, Inc.'s principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.
What is the Commission File Number for MBX Biosciences, Inc.?
The Commission File Number for MBX Biosciences, Inc. is 001-42272.
What is the SIC code for MBX Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for MBX Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 809 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2025-09-26 16:01:50
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MBX Nasdaq Glob
- $18.00 — ock"), at a purchase price per share of $18.00 (the "Offering Price"). Pursuant to the
- $187.5 m — ds from the Offering were approximately $187.5 million, after deducting the underwriting
Filing Documents
- mbx-20250924.htm (8-K) — 46KB
- mbx-ex1_1.htm (EX-1.1) — 323KB
- 0001193125-25-220432.txt ( ) — 533KB
- mbx-20250924.xsd (EX-101.SCH) — 25KB
- mbx-20250924_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2025, MBX Biosciences, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters (collectively, the "Underwriters"), related to an underwritten public offering (the "Offering") of 11,108,055 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), at a purchase price per share of $18.00 (the "Offering Price"). Pursuant to the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 1,666,208 shares of Common Stock at the Offering Price, less any underwriting discounts and commissions. The Offering closed on September 26, 2025. The Common Stock was offered and sold to the public pursuant to the Company's registration statement on Form S-1 (File No. 333-290447) and Form S-1MEF (File No. 333-290498), filed by the Company with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act"), on September 22, 2025 and September 24, 2025, respectively, which became effective on September 24, 2025. Net proceeds from the Offering were approximately $187.5 million, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and short-term investments, primarily to advance development of its three clinical-stage programs and the remainder to fund its discovery research and development activities and additional clinical development, and for general corporate purposes, working capital and capital expenditures. The Underwriting Agreement contains customary representations, warranties and covenants by the Company. It also provides for customary indemnification by each of t
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated September 24, 2025, by and between MBX Biosciences, Inc. and J.P. Morgan Securities LLC and Jefferies LLC. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MBX BIOSCIENCES, INC. Date: September 26, 2025 By: /s/ P. Kent Hawryluk P. Kent Hawryluk, President and Chief Executive Officer